“Favipiravir drugs of domestic production, registered for use in patients with a new coronavirus infection, have proven their effectiveness and safety based on the results of three phases of clinical trials and are successfully used to treat patients with COVID-19,” he told reporters.
As Kuznetsov noted, from the moment of registration, drugs have been included in the system of mandatory labeling of drug movement.
It allows you to control the movement of each package.
“Pharmacovigilance in accordance with the legislation is carried out by Roszdravnadzor.
Cases of serious undesirable side reactions to the use of drugs in our country have not been recorded, "- quotes the assistant RIA Novosti.
Information about possible adverse reactions was obtained from the publication of the information center on pharmacotherapy in patients with COVID-19 "PharmaCOVID", which is intended only for comprehensive information of the professional community, he added.
"The manufacturers of the Japanese drug associate these side effects with the flu, and not with the consequences of using the drug," Kuznetsov explained.
Earlier, Izvestia reported that products based on favipiravir can cause side effects such as night walking and fast running syndromes, as well as an increased risk of falls.
After that, Roszdravnadzor commented on these messages.